CLDX – celldex therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex to Present at Upcoming Investor Conferences
Form 4 Celldex Therapeutics, For: Dec 04 Filed by: Jimenez Freddy A.
Form 144 Celldex Therapeutics, Filed by: Jimenez Freddy A.
Form 4 Celldex Therapeutics, For: Nov 13 Filed by: Wright Richard M.
Form SCHEDULE 13G Celldex Therapeutics, Filed by: Bellevue Group AG
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Commodore Capital LP
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.